Stroke Trial, Recruiting NCT06292117 Sponsor: University of Virginia Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT06292117
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 or older of any gender
  • People who are showing signs of an acute stroke or a brief stroke-like episode (sometimes called a "mini-stroke"), and who are able to take a combination of two blood-thinning medications at the time of screening
  • People who arrive within 24 hours of their symptoms starting, or between 24 and 96 hours after symptoms started if they are already taking or are planned to take a combination of two blood-thinning medications

Who may not be able to join:

  • People who are already taking strong blood-thinning medication (anticoagulants), or who clearly need to start taking them after their stroke event — for example, people who have a heart rhythm condition called atrial fibrillation
  • People who have previously had a bone marrow transplant using donor cells from another person
  • People who have previously had a liver transplant
  • People who are unable to give their own consent and do not have someone available (such as a family member or legal representative) who can give consent on their behalf

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rachael M Stone, PharmD, University of Virginia

Phone: 434-297-6777

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
16 April 2024
Est. completion
1 June 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Percentage of patients discharged from University of Virginia (UVA) Health on dual antiplatelet therapy with a diagnosis of AIS/TIA meeting eligibility criteria upon presentation that are successfully genotyped; Average turnaround time of genotype result from time of collection of blood sample to time result is entered into the electronic health record

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov